July 9, 2024 -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.25%, f……
June 22, 2024 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:23) today announces that its partner Takeda (TSE:4502/NYSE:TAK) has received notification from the European Commission (“EC”) that it has appro……
June 3, 2024 -the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older with the following:advanced or metastatic me……
May 20, 2024-Atara Biotherapeutics, Inc. announced today that Atara has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel?) indicated as monotherapy……
May 22,2024-Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (“VPI” and together with Verona Pharma, the “Company”), have entered into strategic financ……
April 29, 2024-Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa? (alectinib) for adjuvant treatment following tumour resection for patients with an……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號(hào)-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
